Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

544 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
COVID-19 vaccine efficacy in participants with weakened immune systems from four randomized-controlled trials.
Sherman A, Tuan J, Cantos VD, Adeyiga O, Mahoney S, Ortega-Villa AM, Tillman A, Whitaker J, Woodward Davis AS, Leav B, Hirsch I, Sadoff J, Dunkle LM, Gilbert PB, Janes HE, Kublin JG, Goepfert PA, Kotloff K, Rouphael N, Falsey AR, El Sahly HM, Sobieszczyk ME, Huang Y, Neuzil KM, Corey L, Grinsztejn B, Gray G, Nason M, Baden LR, Gay CL. Sherman A, et al. Among authors: grinsztejn b. Clin Infect Dis. 2024 Apr 10:ciae192. doi: 10.1093/cid/ciae192. Online ahead of print. Clin Infect Dis. 2024. PMID: 38598658
Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial.
Grinsztejn B, De Castro N, Arnold V, Veloso VG, Morgado M, Pilotto JH, Brites C, Madruga JV, Barcellos NT, Santos BR, Vorsatz C, Fagard C, Santini-Oliveira M, Patey O, Delaugerre C, Chêne G, Molina JM; ANRS 12 180 Reflate TB study group. Grinsztejn B, et al. Lancet Infect Dis. 2014 Jun;14(6):459-67. doi: 10.1016/S1473-3099(14)70711-X. Epub 2014 Apr 9. Lancet Infect Dis. 2014. PMID: 24726095 Clinical Trial.
HPTN 083-02: factors influencing adherence to injectable PrEP and retention in an injectable PrEP study.
Psaros C, Goodman GR, Lee JS, Rice W, Kelley CF, Oyedele T, Coelho LE, Phanuphak N, Singh Y, Middelkoop K, Griffith S, McCauley M, Rooney J, Rinehart AR, Clark J, Go V, Sugarman J, Fields SD, Adeyeye A, Grinsztejn B, Landovitz RJ, Safren SA; HPTN 083‐02 Study Team. Psaros C, et al. Among authors: grinsztejn b. J Int AIDS Soc. 2024 May;27(5):e26252. doi: 10.1002/jia2.26252. J Int AIDS Soc. 2024. PMID: 38783534 Free PMC article.
SARS-CoV-2 Viral Load in the Nasopharynx at Time of First Infection Among Unvaccinated Individuals: A Secondary Cross-Protocol Analysis of 4 Randomized Trials.
Fisher LH, Kee JJ, Liu A, Espinosa CM, Randhawa AK, Ludwig J, Magaret CA, Robinson ST, Gilbert PB, Hyrien O, Kublin JG, Rouphael N, Falsey AR, Sobieszczyk ME, El Sahly HM, Grinsztejn B, Gray GE, Kotloff KL, Gay CL, Leav B, Hirsch I, Struyf F, Dunkle LM, Neuzil KM, Corey L, Huang Y, Goepfert PA, Walsh SR, Baden LR, Janes H; COVID-19 Prevention Network (CoVPN). Fisher LH, et al. Among authors: grinsztejn b. JAMA Netw Open. 2024 May 1;7(5):e2412835. doi: 10.1001/jamanetworkopen.2024.12835. JAMA Netw Open. 2024. PMID: 38780941 Free PMC article.
Awareness of U = U among Sexual and Gender Minorities in Brazil, Mexico, and Peru: Differences According to Self-reported HIV Status.
Konda KA, Qquellon J, Torres TS, Vega-Ramirez EH, Elorreaga O, Guillén-Díaz-Barriga C, Diaz-Sosa D, Hoagland B, Guanira JV, Benedetti M, Pimenta C, Vermandere H, Bautista-Arredondo S, Veloso VG, Grinsztejn B, Caceres CF. Konda KA, et al. Among authors: grinsztejn b. AIDS Behav. 2024 Apr 25. doi: 10.1007/s10461-024-04336-9. Online ahead of print. AIDS Behav. 2024. PMID: 38662277
Impact of antiretroviral therapy during acute or early HIV infection on virologic and immunologic outcomes: results from a multinational clinical trial.
Crowell TA, Ritz J, Zheng L, Naqvi A, Cyktor JC, Puleo J, Clagett B, Lama JR, Kanyama C, Little SJ, Cohn SE, Riddler SA, Collier AC, Heath SL, Tantivitayakul P, Grinsztejn B, Arduino RC, Rooney JF, van Zyl GU, Coombs RW, Fox L, Ananworanich J, Eron JJ, Sieg SF, Mellors JW, Daar ES; AIDS Clinical Trials Group (ACTG) A5354/EARLIER Study Team. Crowell TA, et al. Among authors: grinsztejn b. AIDS. 2024 Jul 1;38(8):1141-1152. doi: 10.1097/QAD.0000000000003881. Epub 2024 Mar 13. AIDS. 2024. PMID: 38489580 Clinical Trial.
Incidence and Predictors of Tuberculosis-associated IRIS in People With HIV Treated for Tuberculosis: Findings From Reflate TB2 Randomized Trial.
Coelho LE, Chazallon C, Laureillard D, Escada R, N'takpe JB, Timana I, Messou E, Eholie S, Khosa C, Chau GD, Cardoso SW, Veloso VG, Delaugerre C, Molina JM, Grinsztejn B, Marcy O, De Castro N. Coelho LE, et al. Among authors: grinsztejn b. Open Forum Infect Dis. 2024 Jan 22;11(3):ofae035. doi: 10.1093/ofid/ofae035. eCollection 2024 Mar. Open Forum Infect Dis. 2024. PMID: 38486816 Free PMC article. Clinical Trial.
HIV-1 Incidence, Adherence, and Drug Resistance in Individuals Taking Daily Emtricitabine/Tenofovir Disoproxil Fumarate for HIV-1 Pre-Exposure Prophylaxis: Pooled Analysis From 72 Global Studies.
Landovitz RJ, Tao L, Yang J, de Boer M, Carter C, Das M, Baeten JM, Liu A, Hoover KW, Celum C, Grinsztejn B, Morris S, Wheeler DP, Mayer KH, Golub SA, Bekker LG, Diabaté S, Hoornenborg E, Myers J, Leech AA, McCormack S, Chan PA, Sweat M, Matthews LT, Grant R; Global F/TDF PrEP Study Team. Landovitz RJ, et al. Among authors: grinsztejn b. Clin Infect Dis. 2024 Mar 14:ciae143. doi: 10.1093/cid/ciae143. Online ahead of print. Clin Infect Dis. 2024. PMID: 38484128
544 results